Project Grant DP3DK106918

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $120,255 to the University of Colorado-Denver to investigate the mechanisms by which antigen-specific immunotherapy can suppress autoreactive T cells and prolong islet graft survival in a mouse model of autoimmune diabetes. The research aims to determine the differentiation and functional states of antigen-specific CD4...

This federal Project Grant award, R01DK140781, was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The $1,449,016 award aims to use advanced immunoproteomics technologies to comprehensively screen for microbial infections associated with increased or decreased risk of islet autoimmunity and type 1 diabetes in children participating in the TEDDY study. The project...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the role of pH in the pathogenesis of type 1 diabetes (T1D). The $429,000 award to the University of Colorado-Denver will fund a 2-year study to examine how changes in acidity within insulin-producing cells lead to the formation of hybrid insulin peptides that may trigger autoimmune attacks on...

This Project Grant award, ID R01DK140088, was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The $641,794 grant awarded to the Beckman Research Institute of the City of Hope will fund research to elucidate the mechanisms that protect pancreatic beta cells from DNA damage during growth and adaptation, in order to maintain beta cell homeostasis and prevent beta...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $287,000 Project Grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to The Regents of the University of California, San Francisco (UCSF). The grant, which runs from April 2025 to March 2027, aims to determine whether genetic mutations that alter IL-17 signaling contribute to the etiology of autoimmune diabetes. The research will use in vitro and in vivo approaches to understand...

This Cooperative Agreement award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $1,201,988 to Yale University to develop advanced pancreatic-immune organoid models for studying type 1 diabetes (T1D) subtypes and therapeutic responses. The goal is to identify B cell intrinsic features that determine T1D progression and responses to therapies. In Phase 1, the...

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $601,340 to Transchromix LLC to develop a novel therapeutic intervention for early-stage type 1 diabetes (T1D). The research aims to target a translational regulatory mechanism involving the G9A histone methyltransferase, which was found to specifically suppress the pathogenicity of...

This Project Grant award, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), focuses on investigating the role of lymph node stromal cells in maintaining peripheral tolerance and reducing autoimmunity in type 1 diabetes. The primary awardee, The Trustees of Columbia University in the City of New York, will receive $602,531 to conduct research aimed at: Evaluating...

This $310,897 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to develop a first-in-class, islet-targeted antibody therapeutic for Type 1 Diabetes (T1D). The award supports preclinical development and validation activities for this novel antibody therapy, including establishing proof-of-principle for its islet-homing capability, therapeutic...

This federal Cooperative Agreement award, with a total funding amount of $1,207,770.00 and an award date of January 1, 2025, was granted by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award will support research to investigate the role of genetically-controlled thymic epithelial cell (TEC) and hematopoietic stem cell (HSC) abnormalities in driving the development...